- Home
- CEPU vs VRDN Comparison
CEPU vs VRDN Comparison
Compare CEPU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- VRDN
- Stock Information
- Founded
- CEPU 1989
- VRDN 2006
- Country
- CEPU Argentina
- VRDN United States
- Employees
- CEPU N/A
- VRDN N/A
- Industry
- CEPU Electric Utilities: Central
- VRDN Medical Specialities
- Sector
- CEPU Utilities
- VRDN Health Care
- Exchange
- CEPU Nasdaq
- VRDN Nasdaq
- Market Cap
- CEPU 1.6B
- VRDN 1.5B
- IPO Year
- CEPU 2018
- VRDN N/A
- Fundamental
- Price
- CEPU $10.11
- VRDN $18.72
- Analyst Decision
- CEPU Hold
- VRDN Strong Buy
- Analyst Count
- CEPU 1
- VRDN 11
- Target Price
- CEPU $12.00
- VRDN $38.80
- AVG Volume (30 Days)
- CEPU 261.2K
- VRDN 894.1K
- Earning Date
- CEPU 08-11-2025
- VRDN 08-06-2025
- Dividend Yield
- CEPU 3.06%
- VRDN N/A
- EPS Growth
- CEPU N/A
- VRDN N/A
- EPS
- CEPU 0.12
- VRDN N/A
- Revenue
- CEPU $628,806,380.00
- VRDN $305,000.00
- Revenue This Year
- CEPU $11.09
- VRDN N/A
- Revenue Next Year
- CEPU $10.25
- VRDN $35,092.81
- P/E Ratio
- CEPU $10.42
- VRDN N/A
- Revenue Growth
- CEPU N/A
- VRDN 5.90
- 52 Week Low
- CEPU $8.65
- VRDN $9.90
- 52 Week High
- CEPU $16.60
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- CEPU 35.65
- VRDN 55.80
- Support Level
- CEPU $9.97
- VRDN $18.12
- Resistance Level
- CEPU $10.66
- VRDN $20.05
- Average True Range (ATR)
- CEPU 0.55
- VRDN 1.02
- MACD
- CEPU -0.10
- VRDN -0.02
- Stochastic Oscillator
- CEPU 6.41
- VRDN 55.81
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).